epilepsy
Conditions
Interventions
Case series:oxcarbazepine
Sponsors
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. inpatient or outpatient in The second affiliated hospital,school of medicine,Zhejiang university,who are diagnosed with epilepsy and are Chinese adult han patients; 2. aged 18-90 years old; 3. received OXC as monopharmacy or in combination with either the antiepileptic drugs,use a dose to last more than 2 weeks for stable plasma concentration; 4. To fully understand the purpose of this study and to understand possible adverse reactions, volunteer to participate in the experiment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. There are serious adverse reactions to OXC; 2. Have any progressive or degenerative systemic disease or central nervous system disease or brain tumor and other organic brain diseases; 3. Acute epileptic seizures, Such as epilepsy after brain surgery, acute epilepsy induced by viral encephalitis, acute epilepsy after trauma, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genetic testing;Blood drug concentration monitoring;Liver and kidney function;Routine blood; | — |
Countries
China
Contacts
Public ContactHaibin Dai
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Outcome results
None listed